Harkins @DrTrishHarkins et al. Novel diagnostic cytokines in treatment naive PMR. Elevations CXCL-9 (100%), MCP-1 (93%), IL-17A (83%), vs TNF (7%) and IL-6 (67%) @RheumNow #ACR24 Abstr#0881 https://t.co/DbYOn81QJH https://t.co/3eyre00D5d

• Cytokine Profile of Newly Diagnosed Patients with Isolated Polymyalgia Rheumati…
• https://x.com/RichardPAConway/status/1858157645917552730/photo/1

Half of the respondents chose #IL17i for #psoriatic #arthritis #PsA Rx for #Achilles #tendonitis Interesting as lots Of data On #enthesitis wIL23i Likely all Effective #PsA Rx helps #tenosynovitis some have ➡️ data on #efficacy ⬆️ bio rationale #ACR24 @RheumNow @ACRheum https://t.co/wzefjsfdaj

• https://twitter.com/janetbirdope/status/1857188344100221389

The post hoc analysis of the SURPASS study evaluated predictors of radiographic spinal progression in axial spondyloarthritis patients treated with IL-17A (secukinumab) or TNF inhibitors over 2 years. Key findings: - New syndesmophytes: 18.2% (SEC 150 mg), 15.8% (SEC 300 mg),… https://t.co/jke6OHdPjZ

• https://x.com/i/web/status/1858151857870315827

Factors associated w/ secukinumab response in PsA? Analysis of 2.7k pt in EuroSpA Associated w/ favorable response ❗️elevated CRP >10 mg/L ❗️fewer prev tx Associated w/ lower response: ❗️smoking ❗️higher patient global score / HAQ @RheumNow #ACR24 Abstr 2325

This is likely an oversimplification, but I've been looking for exactly this diagram Inhibiting various TYKs/JAKs corresponds to various downstream cytokine inhibition @EricFMorand does it make sense to see this as anifrolumab+ustekinumab? No? @rheumnow #ACR24 Abstr#0662 https://t.co/thti6s5TR3

• https://x.com/EBRheum/status/1857836781628174735/photo/1
• https://x.com/EBRheum/status/1857836781628174735/photo/1

#0600 🔬BKZ achieves sustained impact in PsA ➡️ BE OPTIMAL & BE COMPLETE trials:BKZ 160 mg Q4W bDMARD-naïve & TNFi-IR PsA pts ➡️Pain,function,fatigue & skin showed greatest & sustained reductions @ 2 yrs👇 🎯BKZ offers sustained response in 🔑PsA domains #ACR24 @RheumNow https://t.co/uhzZoOrr3H

• https://x.com/CaoilfhionnMD/status/1857832755188686893/photo/1

#0589 🔬Time to Response in PsA Domains: Secukinumab ➡️Post-hoc analyses, n=1366 🔑Median time (wks) to MCID 👇 🔴Systemic inflammation <2 🔴MSK: ~4 wks (enthesitis~12) 🔴Fatigue~7–8 🔴PASI75~8–12; nails ~24 🩺 Rapid MSK & QoL benefits precede skin/nail #ACR24 @RheumNow https://t.co/WfqkryA1CC

• https://x.com/CaoilfhionnMD/status/1857827721856037222/photo/1

Switching vs cycling - which is better? In PsA & axSpA, a real-world analysis shows that switching to IL-17Ai after TNFi discontinuation may lead to similar or better outcomes compared to cycling to another TNFi. Data from the CorEvitas PsA/SpA Registry. Abstr#0585.… https://t.co/AJP4NBjmzr

• https://x.com/i/web/status/1857827218912849961

PRO-SPIRIT trial data on 1192 PsA pts showed IL-17Ai seemed better than IL-12/23i and IL-23i improving cDAPSA at 3m and as effective as TNFi and JAKi. No much differences seen at 12m. Abst#0076 #ACR24 @RheumNow https://t.co/dScwsmkDOe

• https://x.com/AdelaCastro222/status/1857819668875968932/photo/1

With many treatments for #PsA and #PsO, what are the prescribing trends? Abstract 0604: TNF inhibitors remain the most common (~60%), but over the past 10 years, IL-17i use rose from 0.2% to 19%, and IL-23i from 0.1% to 39.7%! #ACR24 @RheumNow https://t.co/4TnCAkHfuY

• https://x.com/AkhilSoodMD/status/1857820424018755876/photo/1

🤨To cycle or not to cycle TNFi. Abst#0585 studied pts with PsA and axSpA with primary TNFi failure: -Switching to IL17Ai may benefit phGA for arthritis and psoriasis in PsA pts and fatigue in axSpA pts. @AlexisOgdie #ACR24 @RheumNow https://t.co/Jc0cdmrVhI

• https://x.com/AdelaCastro222/status/1857810860795638038/photo/1

Abstract 0587: Among PsA patients (bDMARD-naive & TNF non-responders) treated with Bimekizumab, better disease control was linked to improved work productivity, including ↓ work impairment, ↓ presenteeism, and ↓ activity impairment. #ACR24 @RheumNow https://t.co/sZBjJ9lk39

• https://x.com/AkhilSoodMD/status/1857810357684941164/photo/1